<DOC>
	<DOCNO>NCT01715207</DOCNO>
	<brief_summary>Marfan syndrome ( MFS ) inherit disorder connective tissue morbidity mortality aortic dilatation dissection . The current standard care beta-blocker ( BB ) treatment therapeutic target heart rate . The degree aortic dilatation response BB vary adult MFS . However , aortic stiffness often present , predictor aortic dilatation cardiovascular complication . Aortic stiffness logical therapeutic target adult MFS . Transforming growth factor beta ( TGF-beta ) mediate disease pathogenesis MFS contribute aortic stiffness . Cross-talk TGF-beta system renin-angiotensin system ( RAS ) demonstrate . The angiotensin receptor blocker ( ARB ) , losartan , inhibits TGF-beta activity reverse aortic wall pathology Marfan mouse model . In small cohort study , use ARB therapy ( losartan irbesartan ) significantly slow rate progressive aortic dilatation patient MFS , BB therapy fail prevent aortic root dilatation . In another study , angiotensin convert enzyme inhibitor , perindopril , reduce aortic stiffness aortic root diameter patient MFS take standard BB therapy . Renin inhibitor , aliskiren , study reduce aortic stiffness attenuate aortic dilatation patient MFS . This trial randomize , open-label trial 32 patient Marfan syndrome , treat 6 month aliskiren vs. negative control patient MFS atenolol treatment . MRI aortic pulse wave velocity ( PWV ) distensibility , measurement central BP ( CBP ) augmentation index ( AIx ) perform begin end treatment . A blood drawn serum marker TGF-beta , extracellular matrix turnover inflammation also perform 0 6 month . We plan determine whether aliskiren decrease aortic stiffness significantly negative control patient MFS atenolol treatment .</brief_summary>
	<brief_title>Comparison Study Effect Aliskiren Versus Negative Controls Aortic Stiffness Patients With Marfan Syndrome Under Treatment With Atenolol</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>1 . Diagnosis MFS Ghent criterion and/or genetically prove Fibrillin1 ( FBN1 ) mutation 2 . Age 14 55 year 3 . Betablocker treatment least 3 month 4. subject must receive chronic RAS inhibitor therapy ( i.e . ARBs , ACE inhibitor ) &gt; = 90days prior screen 5 . Written informed consent patient authorized representative must obtain 1. previous medical history aortic surgery and/or dissection 2. significant valve disease require surgery 3. aortic root dimension &gt; 5.5 cm 4. renal dysfunction ( creatinine &gt; upper normal limit ) 5. pregnancy plan pregnancy within 12 month study entry breast feeding woman 6 . Known renal artery stenosis 7 . Hypersensitivity aliskiren excipients 8 . Elevation serum creatinine followup ( &gt; 30 % baseline ) 9 . Diarrhea , result severe dehydration 10 . Development gout ureter stone 11 . Symptomatic hypotension ( SBP &lt; 90 symptom ) 12 . Hyperkalemia 13 . Concomitant use ciclosporin A</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>